{'fraction_non_alphanumeric': 0.047619047619047616, 'fraction_numerical': 0.04081632653061224, 'mean_word_length': 5.184873949579832, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Randomised, double‐blind, placebo controlled pilot study assessing nitroglycerin as a tocolytic

Thirty‐three women in preterm labour were randomised in a double‐blind fashion to receive either transdermal nitroglycerin (n= 17) or placebo (n= 16). Both groups had significant (P < 0.001) change in the cervix prior to randomisation. The primary outcome measure was delivery within 48 hours of randomisation. Fewer women randomised to nitroglycerin treatment (6/17) were delivered within 48 hours, compared with the placebo treatment (10/16) (RR 0.56, 95% CI 0–27 to 1.19). This pilot study lends support to two case series published that suggest that transdermal nitroglycerin may be promising as a safe, effective means for tocolysis.